Evidence map›Paper›PMID 39551813›Full record

ArticleStem cell research & therapy2024

Subcutaneous delivery of mesenchymal stromal cells induces immunoregulatory effects in the lymph node prior to their apoptosis.

Di Zheng, Tejasvini Bhuvan, Natalie L Payne, Swee H M Pang, Senora Mendonca, Mark R Hutchinson, Flyn McKinnirey, Charlotte Morgan, Graham Vesey, Laurence Meagher and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Di ZhengDepartment of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia.
Tejasvini BhuvanDepartment of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia.
Natalie L PayneDepartment of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia.
Swee H M PangDepartment of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia.
Senora MendoncaDepartment of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia.
Mark R HutchinsonSchool of Biomedicine, University of Adelaide, Adelaide, SA, 5005, Australia.
Flyn McKinnireyRegeneus Ltd, 2 Paddington Street, Paddington, NSW, 2021, Australia.
Charlotte MorganRegeneus Ltd, 2 Paddington Street, Paddington, NSW, 2021, Australia.
Graham VeseyRegeneus Ltd, 2 Paddington Street, Paddington, NSW, 2021, Australia.
Laurence MeagherDepartment of Materials Science and Engineering, Monash University, Clayton, VIC, 3800, Australia.
Tracy S P HengDepartment of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3800, Australia. Tracy.Heng@monash.edu.ORCID 0000-0003-4147-8986

Funding

Australian Government Research Training Program Australian Government Research Training ProgramAustralian Research Council FT180100565Australian Research Council IC190100026National Health and Medical Research Council of Australia GNT1162499, GNT2012290
6 · The paper itself

Abstract

backgroundMesenchymal stromal cell (MSC) therapy commonly involves systemic infusion of MSCs, which undergo apoptosis in the lung and induce immunoregulatory macrophages that reduce disease. The relevance of this mode of action, however, is yet to be determined for MSCs administered via other routes. Here, we administered MSCs via subcutaneous (SC) injection into inflamed tissue and investigated the immunomodulatory effects on the local lymph node (LN), which is a major site for the initiation and regulation of immune responses.

methodsA mouse model of localised skin inflammation was established with low-dose lipopolysaccharide (LPS) to in vivo prime adipose-derived MSCs delivered via SC injection. We then analysed the immunomodulatory changes in the LN draining the inflamed tissue, as well as the neutrophil TNF response to LPS re-exposure.

resultsWhen administered directly into the inflamed skin tissue, SC MSC injection induced an expansion of IL-10-producing MerTK

conclusionsMSCs delivered directly into inflamed skin activated immunoregulatory cells in the local LN and inhibited LN responsiveness to subsequent inflammatory challenge. The immunoregulatory effects of SC-injected MSCs in the LN require priming by inflammatory cytokines in the local milieu. Furthermore, SC-injected MSCs exert anti-inflammatory effects in the draining LN prior to their apoptosis, in contrast to intravenously delivered MSCs, where anti-inflammatory effects are linked to their apoptosis.

Indexed as

ApoptosisLymph NodesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsFemaleInflammationInjections, SubcutaneousLipopolysaccharidesMacrophagesMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryLipopolysaccharidesInflammationLymph nodesMacrophagesMesenchymal stem cells

Identifiers

PMID39551813
PMCPMC11572146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.